Tiziana Life Sciences = Submission of a Patent Application for Nasal Administration of Foralumab July 31, 2020 – Posted in: Tiziana Life Sciences (TILS)

31st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients New York/London, July 31, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent…

Tiziana Life Sciences – Proposed Admission to the Official List – Posted in: Tiziana Life Sciences (TILS)

30th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Early notification of proposed admission to the Official List and cancellation of trading on AIM New York/London, 30 July 2020 – Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the “Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (the “Official List”) and admission to trading on…

Tiziana Life Sciences – Investor Webinar July 30, 2020 – Posted in: Tiziana Life Sciences (TILS)

Thursday 30th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020 NEW YORK/LONDON, July 30, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Shailubhai, Ph.D., the Company’s CEO and CSO, will share insight into…

Tiziana Announces Submission of Patent Application on Use of Foralumab July 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

16 July 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy New York/London, July 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a…

Tiziana Life Sciences – Interview to Air on Bloomberg Intl July 10, 2020 – Posted in: Tiziana Life Sciences (TILS)

10 July 2020 Tiziana Life Sciences plc Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with Kunwar Shailubhai, Ph.D., the Company’s CEO and CSO, will air on The RedChip Money Report television program. The interview will air Sunday,…

Tiziana Life Sciences – Totoal Voting Rights & StemPrintER Demerger Update July 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Wednesday 1st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Total Voting Rights and StemPrintER Demerger Update London, New York, 1 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that plans to effect the demerger of StemPrintER from the Group are continuing to be progressed and…

Tiziana Life Sciences – Agreement with STC Biologics June 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 29th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Agreement with STC Biologics Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19. · This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 New York/London – 29…

Tiziana Life Sciences plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 22nd June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 22 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 1,800,000 ordinary shares of 3 pence each (“New Ordinary Shares”)…

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Friday 19th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases · First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies · Transformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 19 June 2020…

Tiziana Life Sciences – Final Results June 18, 2020 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

Thursday 18th June, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Final Results for the Year Ended 31 December 2019 London / New York 18 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces its financial results for the year ended 31 December 2019. This announcement contains inside…

« First
Previous
2
3
4
5
6
...
11
Next
Last »